Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience: reply

Monte, Amato De; Sermann, Giovanni; Sozio, Emanuela; Sbrana, Francesco; Tascini, Carlo

doi:10.1007/s11739-021-02630-1

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The therapeutic effect of ozone is maximized in the early phases of disease development when blood oxygenation is hampered by interstitial edema and alveoli fluid exudates, but only with a limited extension of lung tissue consolidation [32] , [33] . Our approach with respect to enrolled patients stratified according to SIMEU clinical phenotype 2 or 3 was thus based on these pathophysiological arguments.…”

Section: Discussionmentioning

confidence: 99%

CORonavirus-19 mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR) multicentric prospective randomized clinical trial

Sozio¹,

Monte

Sermann

et al. 2021

International Immunopharmacology

Self Cite

View full text Add to dashboard Cite

Background Following positive experience on the use of blood ozonation in SARS-CoV-2, the CORMOR randomized trial was designed to evaluate the adjuvant role of oxygen/ozone therapy in mild to moderate SARS-CoV-2 pneumonia. Methods The trial (ClinicalTrial.gov NCT04388514) was conducted in four different Italian centers (April-October 2020). Patients were treated according to best available standard of care (SoC) therapy, with or without O3-autohemotherapy (O3-AHT). Results A total of 92 patients were enrolled: SoC + O3-AHT (48 patients) were compared to the SoC treatment (44 patients). The two groups differed in steroids therapy administration (72.7% in SoC arm vs. 50.0% in O3-AHT arm; p= 0.044). Steroid therapy was routinely started when it was subsequently deemed as effective for the treatment of COVID-19 disease. No significant differences in mortality rates, length of hospital stay, mechanical ventilation requirement and ICU admission were observed. Clinical improvement in patients with pneumonia was assessed according to a specifically designed score (decrease in SIMEU class, improvement in radiology imaging, improvement in PaO2/FiO2, reduction in LDH and requirement of oxygen therapy ≤5 days). Score assessment was performed on day-3 (T3) and day-7 (TEnd) of O3-AHT treatment. A significant increase in the score was reported at TEnd, in the O3-AHT treatment arm (0 [0-1] in the SoC arm vs. 2 [1] , [2] , [3] the O3-AHT arm; p= 0.018). No adverse events related O3-AHT treatment was observed. Conclusion In mild-to-moderate pneumonia due to SARS-CoV-2, adjuvant oxygen/ozone therapy did not show any effect on mortality, or mechanical intubation but show a clinical improvement a day 7 from randomization in a composite clinical endpoint. Larger Randomized prospective studies alone or in combination with steroids are needed to confirm our results.

show abstract

Section: Discussionmentioning

confidence: 99%

CORonavirus-19 mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR) multicentric prospective randomized clinical trial

Sozio¹,

Monte

Sermann

et al. 2021

International Immunopharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

Insights on the mechanisms of action of ozone in the medical therapy against COVID-19

Chirumbolo

Valdenassi

Simonetti

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

An increasing amount of reports in the literature is showing that medical ozone (O 3 ) is used, with encouraging results, in treating COVID-19 patients, optimizing pain and symptoms relief, respiratory parameters, inflammatory and coagulation markers and the overall health status, so reducing significantly how much time patients underwent hospitalization and intensive care. To date, aside from mechanisms taking into account the ability of O 3 to activate a rapid oxidative stress response, by up-regulating antioxidant and scavenging enzymes, no sound hypothesis was addressed to attempt a synopsis of how O 3 should act on COVID-19. The knowledge on how O 3 works on inflammation and thrombosis mechanisms is of the utmost importance to make physicians endowed with new guns against SARS-CoV2 pandemic. This review tries to address this issue, so to expand the debate in the scientific community.

show abstract

Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience: reply

Cited by 2 publications

References 4 publications

CORonavirus-19 mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR) multicentric prospective randomized clinical trial

CORonavirus-19 mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR) multicentric prospective randomized clinical trial

Insights on the mechanisms of action of ozone in the medical therapy against COVID-19

Contact Info

Product

Resources

About